Dr. Paika Podcast

#Ozempic #Wegovy #Zepbound #GLP1 #weightlossjourney 

Are you taking Wegovy, Ozempic, or Zepbound and feeling like your results have stalled? In this video, board-certified physician Dr. Mohammed Paika breaks down the 5 mistakes that quietly sabotage GLP-1 results — and exactly what to do instead to keep losing fat, protect your muscle, and avoid unnecessary side effects.

Drawing on his experience as a hospitalist and obesity medicine specialist, Dr. Paika walks through dose titration, nutrition, digestion, and lab work — the pieces most people never get told about.

TIMESTAMPS:
0:00 Intro — Why Your Results Might Be Stalling
0:53 Meet Dr. Paika
1:37 Mistake #1: Chasing the Calendar Instead of Your Biology
4:07 Mistake #2: Treating the Medication Like It Replaces the Basics
6:02 Mistake #3: Eating Too Little (and Losing the Wrong Weight)
8:29 Mistake #4: Ignoring What Your Gut Is Telling You
10:47 Mistake #5: Never Checking Your Blood Work
12:27 Final Thoughts + What to Watch Next

REFERENCES:
1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756.
4. Taheri S, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased BMI. PLoS Med. 2004;1(3):e62.
5. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84:475-482.
6. Longland TM, et al. Higher dietary protein during an energy deficit promotes greater lean mass gain and fat loss. Am J Clin Nutr. 2016;103:738-746.
7. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409-1439.
8. Monami M, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer, cholelithiasis). Diabetes Obes Metab. 2017;19(9):1233-1241.
9. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023.
10. Garvey WT, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Tirzepatide #Semaglutide #WeightLoss #ObesityMedicine

Should you increase your GLP-1 dose — or actually decrease it? Before you touch that pen, run through the 7 checks I use with my own patients (and on myself) to decide whether it's time to go up, hold steady, or come down. This isn't about chasing the highest dose on the label — it's about finding the dose you can tolerate and sustain for the long run.

I'm Dr. Mohammed Paika — internal medicine physician, board-certified in obesity medicine, and a GLP-1 user myself. In this video I walk through dose duration, your real weight trend, hunger and food noise, tolerability, plateaus vs. real stalls, the rest of your system (protein, sleep, training), and your actual goals — with real hospitalist cases on what happens when dosing goes wrong.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

TIMESTAMPS
0:00 – Intro: should you change your GLP-1 dose?
2:12 –  How long have you been at this dose?
4:00 – What does your real weight trend say?
6:36 – Free GLP-1 Diet Cookbook
7:13 –  What's happening with your hunger?
9:05 –  How well are you tolerating this dose?
11:17 – The GLP-1 Masterclass
11:58 –  Are you really at a plateau?
13:23 –  What else changed in your system?
14:55 – What are you actually trying to achieve?
16:45 – Physician safety reminder
17:34 – What's next

References

Zepbound (tirzepatide) injection, for subcutaneous use. Highlights of Prescribing Information. Eli Lilly and Company. pi.lilly.com/us/zepbound-uspi.pdf; U.S. Food and Drug Administration label, accessdata.fda.gov.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
Monami M, Nreu B, Scatena A, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233-1241.
Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621-628.
Hall KD. Predicting metabolic adaptation, body weight change, and energy intake in humans. Lancet Diabetes Endocrinol. 2014;2:395-406.
Longland TM, Oikawa SY, Mitchell CJ, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. Am J Clin Nutr. 2016;103:738-746.
Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength. Br J Sports Med. 2018;52:376-384.
Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr. 2025;122:344-367.
Garvey WT, Mechanick JI, Brett EM, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#BPC157 #PeptideTherapy #TendonHealing #RegenerativeMedicine #healthscience 

BPC-157 is everywhere right now — but does the evidence actually justify putting this peptide into your body? In this video, Dr. Mohammed Paika (board-certified internal medicine & obesity medicine) breaks down what BPC-157 actually does, what the animal research shows, what we really know about human safety, and the one theoretical risk that concerns him most as a physician.

BPC-157 is not FDA-approved for any human use.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316

Timestamps

0:00 – Intro: Does the evidence justify this?
0:44 – What BPC-157 Actually Is
2:19 – How BPC-157 Works (The Mechanism)
4:18 – The Musculoskeletal Evidence
7:51 – Gut Health
10:58 – Brain & Nervous System
13:14 – Cardiovascular Health
14:07 – The Honest Safety Picture
16:20 – What Human Data We Actually Have
19:24 – The Risk That Concerns Me Most (Cancer)
21:46 – Who Should Actually Consider This
24:26 – The Regulatory Reality (FDA, 2026)

References
Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.
Krivic A, et al. Achilles detachment in rat and BPC 157: tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989.
Cerovecki T, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161.
Staresinic M, et al. Effective therapy of transected quadriceps muscle in rat: BPC 157. J Orthop Res. 2006;24(5):1109-1117.
Novinscak T, et al. BPC 157 as effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725.
Šebečić B, et al. Osteogenic effect of BPC-157 on segmental bone defect healing in rabbits. Bone. 1999;24(3):195-202.
Duzel A, et al. BPC 157 in colitis and ischemia/reperfusion in rats. World J Gastroenterol. 2017;23(48):8465-8488.
Vuksic T, et al. BPC 157 heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768-777.
Sikiric P, et al. BPC 157 effects on stomach mucosa integrity and blood pressure. Life Sci. 1994;54(5):PL63-68.
Park JM, et al. BPC 157 rescued NSAID-cytotoxicity via intestinal permeability. Curr Pharm Des. 2020;26(25):2971-2981.
Tudor M, et al. Traumatic brain injury in mice and BPC 157 effect. Regul Pept. 2010;160(1-3):26-32.
Vukojević J, et al. BPC 157 in hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726.
Gjurasin M, et al. Peptide therapy with BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41.
Perovic D, et al. BPC 157 improves healing course of spinal cord injury in rats. J Orthop Surg Res. 2019;14:199.
Zemba Cilic A, et al. BPC 157 counteracts catalepsy in rat schizophrenia-like models. Behav Brain Res. 2021;396:112919.
Sikiric P, et al. Antidepressant effect of BPC 157 in Porsolt's test and chronic stress in rats. J Physiol Paris. 2000;94(2):99-104.
Xu C, et al. Preclinical safety evaluation of BPC-157. Regul Toxicol Pharmacol. 2020;114:104665.
He W, et al. Pharmacokinetics of BPC-157 in rats and dogs. Front Pharmacol. 2022;13:1026182.
Lee E, et al. Effect of BPC-157 on interstitial cystitis symptoms: a pilot study. Altern Ther Health Med. 2024;30:12-17.
Lee E, Burgess C. Safety of IV infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med. 2025.
Lee E, Padgett B, et al. Intra-articular BPC 157 for knee pain. Altern Ther Health Med. 2021;27(S1).
ClinicalTrials.gov. Study of BPC-157 in healthy volunteers. NCT02637284. Withdrawn.
Nair AB, Jacob S. Dose conversion between animals and humans. J Basic Clin Pharm. 2016;7(2):27-31.
U.S. FDA. Pharmacy Compounding Advisory Committee vote on BPC-157, July 23, 2026. See also: Pharmaceutical Executive, July 24, 2026.
U.S. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Semaglutide #Tirzepatide #Inflammation #obesitymedicine 

GLP-1 drugs like semaglutide and tirzepatide don't just lower weight and blood sugar — the research increasingly shows they change inflammation too. In this video, Dr. Mohammed Paika (board-certified internal medicine + obesity medicine, hospitalist) breaks down what CRP actually measures, why chronic inflammation happens, how much of the anti-inflammatory effect is really just weight loss versus a separate biological pathway, and why tirzepatide's second receptor (GIP) may make it different from semaglutide.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps

0:00 Introducing the GLP-1 inflammation question
1:03 Who I am and why I'm covering this
2:54 What CRP actually measures on your labs
5:19 What inflammation really is (the alarm system)
7:35 Why visceral fat sounds a false alarm
10:23 Free GLP-1 Diet Cookbook
11:09 The puzzle: is it just weight loss?
15:01 Where the independent anti-inflammatory signal comes from
17:21 Why tirzepatide's GIP receptor might be different
20:30 What this does NOT mean (important caution)
21:34 Bringing it all together
22:42 Closing thoughts + GLP-1 Masterclass

References

Wong CK, et al. Central GLP-1 receptor activation inhibits TLR agonist-induced inflammation. Cell Metab. 2024;36(1):130-143.e5.
Ren Y, Chen Y. GLP-1 RAs and circulating inflammatory markers in T2D: meta-analysis. Diabetes Obes Metab. 2025.
Semaglutide 2.4mg and CRP in STEP 1, 2, 3: exploratory analyses. eClinicalMedicine. 2023;55:101737.
Semaglutide and hsCRP: SUSTAIN/PIONEER analyses. Cardiovasc Diabetol. 2022;21:184.
Rodbard HW, et al. PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272-2281.
Semaglutide and hsCRP in SELECT: prespecified secondary analysis. PMID: 42610271.
Anti-inflammatory effects of tirzepatide: meta-analysis. Rev Endocr Metab Disord. 2025.
Sattar N, et al. Tirzepatide and hsCRP: SURPASS-4 post hoc. Circulation. 2023;148(suppl 1).
Inflammatory biomarkers with tirzepatide: SURMOUNT-1/2 post hoc. Circulation. 2024;150(suppl 1).
Wong CK, Drucker DJ. Anti-inflammatory actions of GLP-1-based therapies. J Clin Invest. 2025;135(21):e194751.'

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #Mounjaro #Semaglutide #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine 

If you're on tirzepatide or semaglutide and the scale isn't moving the way you expected, this video is for you. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine — I've been dealing with these medications in the hospital since they first came out, and I've managed my own weight through diet and training alone for over a decade. In this video I break down what tirzepatide and semaglutide actually are, why they were invented, how they work in your body, the exact dosing timeline, why the shot is only once a week, what you have to do around the medication for it to actually work, and what happens once you hit your goal weight. Most important is what to do besides taking the medication which is what my GLP-1 Masterclass is designed to teach you. 

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps
0:00 Intro — Why These Drugs Weren't Built For Weight Loss
1:39 My Story — Both Sides Of The Stethoscope
3:16 Step 1 — Know What You're Actually Taking
4:14 Step 2 — Know Why It Exists
5:03 Step 3 — How It Works In Your Body (Trial Data & Patient Case)
8:02 Where To Go Deeper (Masterclass & Free Cookbook)
8:32 Step 4 — The Dose: Where You Start, Where You End Up
9:57 Step 5 — Why It's Only Once A Week
10:45 Step 6 — What You Have To Do Around The Medication
12:59 Step 7 — What Happens When You Get There
14:13 Closing Thoughts

References
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
Rubino D, et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325:1414–1425.
FDA. ZEPBOUND (tirzepatide) Prescribing Information, label 217806.
FDA. WEGOVY (semaglutide) Prescribing Information, label 215256.
Paika M. GLP-1 Masterclass, Ch. 5 & 11 (drmohammedpaika.com).

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Peptides #PeptideTherapy #GLP1 #AntiAgingMedicine #bpc157 

Peptides didn't start with a wellness influencer — they started with a dying 14-year-old boy in 1922 and a shot of insulin. Today that same category includes everything from FDA-approved medications to unregulated research chemicals sold online with zero oversight.

In this video I break down over 20 peptides — from BPC-157 and TB-500 to semaglutide, tirzepatide, retatrutide, and the newest FDA regulatory update on compounding access — organized into the three levels of biology they actually work on: cellular energy, tissue repair, and systemic control (your hormones, metabolism, and nervous system).

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS

0:00 – Intro — why peptides aren't what you think
1:21 – What a peptide actually is
3:24 – Why "your body recognizes it" doesn't mean it's right for you
5:15 – The three-layer framework
6:18 – Layer One: Cellular energy (Epitalon, MOTS-c, SS-31)
11:58 – Layer Two: Tissue repair (BPC-157, TB-500, GHK-Cu)
18:08 – Layer Three: Hormones (Sermorelin, Ipamorelin, CJC-1295, Tesamorelin)
21:36 – Layer Three: Metabolism (Semaglutide, Tirzepatide, Retatrutide)
26:24 – Layer Three: Brain & nervous system (Semax, Selank, Dihexa, Cerebrolysin)
31:40 – The most expensive mistake I see
33:44 – What to do with this

References
WHO — Diabetes Fact Sheet: ~9 million people worldwide live with type 1 diabetes and require insulin injections for survival
National Institute on Aging — "Exendin-4: From Lizard to Laboratory...and Beyond"
PubMed — "The Development of Byetta (Exenatide) From the Venom of the Gila Monster" (PMID 21194543)
Cell Metabolism (2015) — "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance"
Khavinson, Bondarev, Butyugov — "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, 2003
Khavinson et al. — "Effect of Epitalon on Biomarkers of Aging, Life Span and Spontaneous Tumor Incidence in Female Swiss-Derived SHR Mice," Bulletin of Experimental Biology and Medicine
Johns Hopkins ICTR; Pharmacy Times; Drugs.com — FDA accelerated approval of Forzinity (elamipretide/SS-31) for Barth syndrome, September 19, 2025
Genetics in Medicine — Phase 2/3 randomized trial of elamipretide (SS-31) in Barth syndrome (PMC7935714)
Pickart et al. — "Regenerative and Protective Actions of the GHK-Cu Peptide in the Skin and Other Tissues" (PMC6073405)
USADA — Athlete Advisory on 2022 WADA Prohibited List changes (BPC-157)
Sport Integrity Australia — Thymosin Beta-4 (TB-500) substance profile
Pharmaceutical Executive — "FDA Votes to Loosen Restrictions for Four Peptides" (July 23, 2026); STAT News coverage of the same PCAC vote (BPC-157 8-6, TB-500 8-6, KPV 8-6, MOTS-c 7-5 — advisory only, formal rulemaking still pending)
CBS News — "Stallone Pleads Guilty to Import Charge" / "Australia Fines Sly for Toting Hormones" (2007); Hollywood Reporter (2007); Taipei Times wire report (May 22, 2007)
FDA — Approved labeling for EGRIFTA (tesamorelin for injection)
Jastreboff et al., New England Journal of Medicine, 2023 — Phase 2 trial of retatrutide
Pharmaceutical Journal / AJMC / Pharmacy Times, May 2026 — TRIUMPH-1 topline results (Eli Lilly; peer review pending)
Alzheimer's Drug Discovery Foundation, Cognitive Vitality — Dihexa peptide profile
NeurologyLive / FierceBiotech — Fosgonimeton LIFT-AD (Nov 2024) and SHAPE (Dec 2023) trials, both missed primary endpoint
Ziganshina LE et al., Cochrane Database of Systematic Reviews, 2020 — Cerebrolysin for acute ischaemic stroke

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Phentermine #WeightLoss #ObesityMedicine #GLP1 #weightlosstips 

The #1 mistake I see patients make on phentermine isn't a dosing error — it's that they stop eating. In this video, Dr. Mohammed Paika (board-certified in Internal Medicine and Obesity Medicine, 20 years as a hospitalist) breaks down exactly why appetite suppression gets confused with starvation, the real physiology of what happens to your metabolism and muscle when you under-eat on phentermine, a patient case from the hospital floor you won't forget, and the protein-first framework to actually keep the weight off long-term.

You'll learn:
– What phentermine actually does in your body (and why it's still the most-prescribed weight-loss medication in the U.S.)
– The 3-stage physiology of "starvation mode" — and the real data behind it
– A protein-first meal-timing framework you can start today
– Why resistance training is non-negotiable for protecting your metabolism
– Why phentermine isn't your only option — and how to know if it's the right one for you

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps
0:00 Intro — The Mistake Almost Everyone Makes on Phentermine
1:05 What Phentermine Actually Does In Your Body
3:17 The Real Mistake: Not Eating
4:21 Why It Feels Like Winning At First
5:24 The 3 Stages of Starvation Mode
9:28 Free Resource: The GLP-1 Diet Cookbook
10:20 The Patient I'll Never Forget
12:26 What To Eat Instead: The Protein-First Framework
15:44 Protect Your Muscle & Metabolism
17:56 Phentermine Isn't Your Only Option
19:27 Playing The Long Game
21:43 The Bottom Line + Free Resources

References
U.S. FDA, Phentermine Hydrochloride prescribing information (Initial Approval 1959)
Fothergill E, et al. Obesity. 2016;24(8):1612–1619
Lewis KH, et al. Obesity. 2019;27(4):591–602
Hunter GR, et al. Obesity. 2008;16(5):1045–1051
Mifflin MD, et al. Am J Clin Nutr. 1990;51(2):241–247
Wang Z, et al., organ metabolic rate research; Javed F, et al., body composition research
NBC Sports / Olympics.com / EssentiallySports — reporting on Michael Phelps's diet
Lewis KH, Gudzune KA, Ard JD. Current Obesity Reports. 2024;13(1):132–140

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Zepbound #Wegovy #Tirzepatide #Semaglutide #glp1 

Zepbound and Wegovy are the two most talked-about weight loss medications right now — but the headlines comparing them skip the context that actually matters. In this video, I break down how tirzepatide (Zepbound) and semaglutide (Wegovy) actually work in your body, compare the real clinical trial data — including the new SURMOUNT-5 head-to-head trial — and walk through the side effects, cost, and questions you need to bring to your physician before choosing between them.

I'm Dr. Mohammed Paika — board-certified in Internal Medicine and Obesity Medicine, and a practicing hospitalist for over 15 years. I built DrMohammedPaika.com to give people real, evidence-based guidance on GLP-1 medications, nutrition, and exercise, because a prescription without a plan for your muscle, your nutrition, and your training is only half a treatment.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps

00:00 Introduction
01:10 Who's Giving You This Information
03:22 Wegovy vs. Zepbound: The Timeline
04:52 How These Medications Actually Work
07:28 Dosing and What's New in 2026
10:01 Side Effects (And a Case From My Hospital)
13:11 Who Actually Qualifies
14:09 The Individual Trial Data: STEP 1 vs. SURMOUNT-1
15:22 SURMOUNT-5: The Head-to-Head Trial
17:28 Why the Average Doesn't Decide Your Case
18:17 The Part Everyone Skips: Your Muscle
20:16 What These Medications Cost in 2026
22:36 A Patient Case That Changed My Approach
24:14 Questions to Ask Your Physician
25:22 The Bottom Line
26:26 Where to Go From Here

References 

Aronne LJ, et al. SURMOUNT-5, N Engl J Med (2025); Eli Lilly official results announcement, investor.lilly.com
Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157
U.S. FDA approval history: semaglutide (Ozempic) 2017; semaglutide (Wegovy) June 2021
Samms RJ, Coskun T, et al. Trends Endocrinol Metab. 2020;31(6):410-421
Coskun T, Sloop KW, et al. Mol Metab. 2018;18:3-14
Wegovy (semaglutide) U.S. Prescribing Information, Novo Nordisk
Zepbound (tirzepatide) U.S. Prescribing Information, Eli Lilly
FDA approval of oral semaglutide (Wegovy pill), OASIS-4 trial, 2025
Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002
Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216
He L, et al. JAMA Intern Med. 2022 (DOI 10.1001/jamainternmed.2022.0338)
Neeland IJ, et al. Diabetes Obes Metab. 2024 (DOI 10.1111/dom.15728)
Prado CM, Phillips SM, et al. Lancet Diabetes Endocrinol. 2024 (DOI 10.1016/S2213-8587(24)00272-9)
NovoCare.com, Wegovy Cost, Coverage & Savings Resources, 2026
Eli Lilly investor announcement, LillyDirect Self Pay Journey Program pricing, 2026

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Supplements #Longevity #Creatine #Omega3 #glp1medications 

Feeling overwhelmed by the supplement aisle and not sure which five actually move the needle? As a board-certified internal medicine and obesity medicine physician (and a certified personal trainer), I'm cutting through the noise and giving you the only five supplements I actually recommend for longevity, performance, and overall health — with the real dose, the form that's actually absorbed, and the timing that matters, backed by the studies behind every claim.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps:
0:00 – Intro: the 5 supplements that actually work
1:10 – #5 Creatine: dose, form, and the brain benefit nobody mentions
6:46 – #4 Magnesium: the mineral running 300 systems you never think about
11:51 – #3 Vitamin D: how deficient is "deficient"
16:51 – Before we continue (free newsletter + GLP-1 Diet Cookbook)
17:42 – #2 Fiber: the supplement nobody thinks is sexy
22:51 – #1 Omega-3: heart, brain, and muscle recovery in one mechanism
26:57 – If you're on a GLP-1 medication: the real risk
29:31 – Where to go from here

References:
1.Kreider RB, et al. ISSN position stand: creatine supplementation dosing. J Int Soc Sports Nutr. 2017;14:18. — Full text (PMC)
2. Creatine supplementation protocols on body composition: GRADE-assessed dose-response meta-analysis. J Int Soc Sports Nutr. 2024. — PubMed
3. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the U.S. Nutrition Reviews. 2012;70(3):153–164. — PubMed
4. NIH Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. — ods.od.nih.gov
5. Prevalence, trend, and predictor analyses of vitamin D deficiency in the U.S. population, 2001–2018. Frontiers in Nutrition. 2022. — Full text
6. Demay MB, et al. Vitamin D for the Prevention of Disease: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947. — PubMed
7. Holick MF, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: Endocrine Society Guideline. J Clin Endocrinol Metab. 2011;96(7):1911–1930. — Journal page
8. Dietary fiber intake and all-cause/cause-specific mortality: dose-response meta-analysis. Frontiers in Nutrition. 2023;10:1153165. — Full text
9. Kapoor MP, et al. Partially hydrolysed guar gum and postprandial glucose/lipid response. Journal of Functional Foods. 2016. — Journal page
10. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl (REDUCE-IT). NEJM. 2019;380:11–22. — NEJM
11. Harris WS, von Schacky C. The Omega-3 Index. Preventive Medicine. 2004;39(1):212–220. — Journal page
12. STEP 1 DXA body-composition substudy (semaglutide). — PMC
13. Look M, et al. SURMOUNT-1 body composition analysis (tirzepatide). Diabetes, Obesity and Metabolism. 2025. — PubMed

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Retatrutide #GLP1 #WeightLoss #ObesityMedicine #metabolichealth 

Retatrutide is producing weight loss results we used to only see after bariatric surgery — but the medication is only half the story. In this video, Dr. Mohammed Paika (board-certified in internal medicine and obesity medicine) breaks down the five decisions he'd make before ever taking a first dose: how to find the right dose instead of chasing the highest one, why your heart rate and mood deserve the same attention as the scale, how to protect your muscle while the weight comes off, how to build a supplement plan instead of guessing, and why the medication should never be allowed to do all the work on its own.

Important: as of this video, retatrutide is still investigational and not yet FDA approved. Eli Lilly has completed three positive Phase 3 trials and plans to file for approval in Q1 2027. Right now it's accessible only through clinical trials or a narrow compassionate-use program — this video is the plan to have ready before that changes.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316

Timestamps 
0:00 – Intro
2:38 – Where Things Stand: Is Retatrutide FDA Approved?
4:35 – Rule 1: Dosing Is Not a Competition
10:37 – Rule 2: The Scale Doesn't See Everything (Heart + Mood)
16:50 – Rule 3: Muscle Is Not Optional
21:30 – Rule 4: Supplements Need a Strategy, Not a Guess
24:26 – Rule 5: Don't Let the Medication Do All the Work
28:15 – The Five Decisions That Actually Matter
29:18 – What To Do Next

References
TRIUMPH-1 phase 3 trial results (weight loss %, BMI outcomes, discontinuation rates) — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
TRIUMPH-1 trial summary and safety profile — https://www.hcplive.com/view/retatrutide-weight-loss-endpoints-phase-3-obesity-trial
Retatrutide phase 2 data — mechanism and heart rate increase (~6.7 bpm), Doggrell, Expert Opinion on Investigational Drugs, 2023 — https://pubmed.ncbi.nlm.nih.gov/37947489/
FDA Drug Safety Communication — removal of suicidal ideation/behavior warning from GLP-1 receptor agonist labels (January 2026) — https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
Lilly TRIUMPH-2 and TRIUMPH-3 phase 3 results and planned Q1 2027 BLA submission — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Retatrutide access status, August 2026 — https://www.ajmc.com/view/lilly-expands-retatrutide-access-amid-doctor-pushback
Lean body mass loss data (SURMOUNT-1, STEP-1) and 2025 joint medical-society advisory — https://www.healio.com/news/endocrinology/20251114/muscle-matters-the-challenge-of-preserving-lean-mass-during-obesity-treatment
Fothergill et al., "Persistent metabolic adaptation 6 years after The Biggest Loser competition," Obesity, 2016 — https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538
American Medical Association's 2013 classification of obesity as a chronic disease — https://abcnews.go.com/Health/american-medical-association-classifies-obesity-disease/story?id=19439304 and https://obesitymedicine.org/blog/ama-adopts-policy-recognize-obesity-disease/
"GLP-1 personality" — patient-reported emotional blunting and researcher commentary — https://health.yahoo.com/your-body/weight-management/weight-loss/article/what-is-ozempic-personality-125300474.html
Protein targets and resistance-training rationale — Dr. Paika's GLP-1 Masterclass, Chapters 7 & 13 (internal course material)

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Viewing this content does not create a doctor-patient relationship between you and Dr. Paika. Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.